scholarly journals Feasibility and Acceptability of Medical Abortion at BPKIHS

1970 ◽  
Vol 8 (3) ◽  
pp. 142-146
Author(s):  
Ajay Agrawal ◽  
Mohan C Regmi ◽  
Dhruba Kumar Uprety ◽  
Hanoon Pokhrel ◽  
Pappu Rijal
Keyword(s):  
Pregnant Women ◽  
Medical Abortion ◽  
Termination Of Pregnancy ◽  
Prospective Data ◽  
Operational Requirement ◽  
Oral Misoprostol ◽  
Early Abortion ◽  
Home Administration ◽  
At Home

Objective: To test the feasibility and acceptability of a simplified mifepristone-misoprostol regimen for early abortion at BPKIHS.Methods: Pregnant women (n=100) with amenorrhea of 56 days or less seeking termination of pregnancy received 200mg of oral mifepristone followed 48hours later by 400 μg of oral misoprostol, administered either at home or at the clinic. Prospective data were collected to determine the women.s experience, abortion outcome, and the operational requirement for providing the method.Result: Most (91%) of the 88 women with known outcomes had successful medical abortions. Given the option, most (95.4%) women elected to administer the misoprostol at home. Conclusion: A simplified medical abortion protocol, including home administration of misoprostol, is highly safe, effective acceptable and feasible in our setting. Keywords: medical abortion; mifepristone; misoprostol DOI: 10.3126/hren.v8i3.4205Health Renaissance, September-December 2010; Vol 8 (No.3);142-146

scholarly journals Mifepristone and Oral Misoprostol for Early Medical Abortion

1970 ◽  
Vol 7 (2) ◽  
pp. 127-130 ◽  
Author(s):  
V Shrivastava ◽  
A Shrivastava
Keyword(s):  
Pregnant Women ◽  
Success Rate ◽  
Research Council ◽  
Medical Abortion ◽  
Termination Of Pregnancy ◽  
Medical Termination Of Pregnancy ◽  
Oral Misoprostol ◽  
Medical Termination ◽  
Health Research Council ◽  
Good Success Rate

Background: Combined mifepristone and misoprostol is the best method of medical termination of pregnancy. The study is undertaken to find out the success rate, acceptability, efficacy and patient satisfaction of medical abortion in pregnant women with 49 days of gestation. Methods: The pregnant women with amenorrhea of 49 days or less seeking termination of pregnancy received were studied. The 200 mg of oral mifepristone and followed 48 hours later with 600 microgram of oral misoprostol were given. Results: The success rate with the regime was 47 (94%) and 49 (98%) were satisfied. Weakness 24 (48%), Nausea 10 (20%), diarrhea 12 (25%), needing analgesic 4 (8%) were the side effects of the combined regime. Conclusions: Medical termination of pregnancy with combination of mifepristone and oral misoprostol has a good success rate. The side effect of the regimen in our setup is less and well accepted. Majority of the patient are satisfied with medical termination of pregnancy. Key words: medical abortion; misoprostol; mifepristone DOI: 10.3126/jnhrc.v7i2.3021 Journal of Nepal Health Research Council Vol.7(2) Apr 2009 127-130

scholarly journals Early pregnancy termination with a simplified mifepristone: Medical abortion outpatient regimen

1970 ◽  
Vol 7 (3) ◽  
pp. 209-212 ◽  
Author(s):  
N Chuni ◽  
TS Chandrashekhar
Keyword(s):  
Pregnancy Termination ◽  
Medical Abortion ◽  
Global Public Health ◽  
Public Health Importance ◽  
Safe Abortion ◽  
Nulliparous Women ◽  
Oral Misoprostol ◽  
Medical Termination ◽  
A Prospective Study ◽  
Home Administration

Background: An estimated 30 million abortions are performed worldwide every year. Many women do not have access to abortion and die of complications after illegal abortions. Medical abortion could provide greater access to safe abortion services; availability of the procedure is, therefore, of global public health importance. Aim: The aim was to study the efficacy of lowered dose of Mifepristone in medical abortion. Materials and methods: One hundred and twelve cases with a pregnancy of 63 days duration or less were enrolled in a prospective study using a lowered dose of 200mg Mifepristone followed, 48 hours later, by home administration of 400μg Misoprostol orally. At the second visit, on day 15, outcome and adverse effects were analysed. Women who failed to undergo a complete abortion were further managed by surgical evacuation of uterus. Results: The mean gestational age was 50.6 days. The rates of complete abortion were 92.8%, 83 % and 80 % in the ≤49 days group, 50 to 56 days and 57 to 63 days group respectively. Vaginal bleeding emerged as the biggest reason for medically indicated termination. Nulliparous women had a greater frequency of side effects, though values did not reach statistical signifi cance. Conclusion: This regimen of a lower dose of 200mg Mifepristone, followed by home administration of 400μg oral Misoprostol 48 hours later is safe and highly effective especially in pregnancies of up to 49 days duration. Key words: Mifepristone; Medical termination of pregnancy (MTP) DOI: 10.3126/kumj.v7i3.2725 Kathmandu University Medical Journal (2009) Vol.7, No.3 Issue 27, 209-212

scholarly journals A comparative study of sublingual versus oral misoprostol following oral mifepristone for second trimester termination of pregnancy

2019 ◽  
Vol 8 (2) ◽  
pp. 498
Author(s):  
Ruchi Gupta ◽  
Krishna Priya Banerjee ◽  
Reena Pant
Keyword(s):  
Success Rate ◽  
Medical Abortion ◽  
Oral Route ◽  
Termination Of Pregnancy ◽  
Second Trimester ◽  
Oral Misoprostol ◽  
Sublingual Misoprostol ◽  
Group A ◽  
The Mean ◽  
Group B

Background: The objective of this study is to assess the effectualness and safety of sublingual versus oral misoprostol following oral mifepristone for second trimester termination of pregnancy.Methods: This institution based contingent study was conducted on 220 women requesting for mid-trimester termination of pregnancy between 12-20 weeks with legal indication as per Govt. MTP act. After excluding the women as per exclusion criteria, they were randomly allocated into two groups (Group A Sublingual, Group B Oral), the women received 200 mg oral mifepristone followed by sublingual or oral misoprostol 400µg three hourly for a maximum of 5 doses 48 hours later. The course of misoprostol was reiterated if women failed to abort in 24 hours.Results: The mean induction-abortion interval of Group-A and Group -B was 4.02±1.39 hours and 6.44±1.79 hours respectively. The mean dose of misoprostol in Group–A and Group-B was 680±220.4µg and 1003.6±274.9µg. Hence mean Induction-abortion interval and dose were shortened in  Group-A as compare to Group-B (p <0.05). There was 100% success rate noticed via both routes. Evacuation was done in 4 (3.64%) women in Group-B as compare to only 1 (0.91%) in Group-A . The acceptability was significantly more in Group-B (100%) as compare Group-A (52.73%), probably because of unpleasant taste of sublingual misoprostol. All side effects (Nausea, pain, headache, and diarrhea) were common in both the Groups, only fever was significantly more common in sublingual group as compare to oral group (p<0.05).Conclusions: From present study authors conclude that, sublingual misoprostol when combined with mifepristone is effective for medical abortion in second trimester in terms of effectualness, endurability and success rate than oral route.

scholarly journals Medical methods of abortion using lowest effective dose of mifepristone and misoprostol: case study of 100 women

2017 ◽  
Vol 6 (7) ◽  
pp. 2753
Author(s):  
Mehvish Anjum ◽  
Nivedita D.
Keyword(s):  
Effective Dose ◽  
Failure Rate ◽  
Side Effect ◽  
Medical Abortion ◽  
Termination Of Pregnancy ◽  
Common Side Effect ◽  
Prospective Clinical Study ◽  
Chi Square ◽  
Early Abortion

Background: Medical abortion or Medical Methods of abortion (MMA) (or Chemical abortion) is defined as “the non-surgical way of termination of termination of pregnancy by a drug or combination of drugs”. With introduction of MMA there has been a steep rise in abortion related complications due to irrational use of these drugs. This study is undertaken using lowest effective dose of mifepristone and misoprostol in 100 women willing for termination of pregnancy with period of gestation <49 days to study the efficacy, side effects and failure rate. Present study emphasizes on using MMA by proper selection of patient, adhering to proper schedule under provision of MTP Act (counselling, consent, examination, confirmation of pregnancy, prescription by a registered medical practioner) in order to enhance efficacy and avoid complications.Methods: Prospective Clinical Study consist of use of single dose of 200mg of mifepristone orally followed by misoprostol (400µg) by vaginal route for terminating pregnancy in ≤49 days of gestation. Statistical analysis done by Chi square test.Results: In this study, success rate i.e. complete abortion without requiring surgical procedure was 96%and failure rate was 4%. Nausea (56%) is the most common side effect of Mifepristone. Chills (33%) is the most common side effect of Misoprostol. Mean Induction Abortion Interval is 2.17±1.2 hrs. Mean Duration of Bleeding is 7.79±4.42 days.Conclusions: Medical abortion is a promising method of early abortion in a developing country like India as it requires no technical skills and manpower with a good safety profile.

Impact of self-administration of misoprostol for early medical abortion: a prospective observational cohort study

2019 ◽  
Vol 45 (4) ◽  
pp. 296-301 ◽  
Author(s):  
Rebecca Elizabeth Finch ◽  
Kevin McGeechan ◽  
Anne Johnstone ◽  
Sharon Cameron
Keyword(s):  
Success Rate ◽  
Medical Abortion ◽  
Self Administration ◽  
Significant Difference ◽  
Observational Cohort ◽  
Effective Contraception ◽  
Long Acting ◽  
The Impact ◽  
Home Administration ◽  
At Home

IntroductionIn October 2017, Scotland legalised the home use of misoprostol for the purpose of early medical abortion (EMA). Women up to 9+6 weeks’ gestation can now self-administer the drug at home, 24–48 hours after receiving mifepristone in the clinic.ObjectiveTo evaluate the impact of this change on the uptake and success rate of EMA, and on the provision of effective contraception on discharge.MethodsA prospective observational study was conducted to compare the outcomes of two cohorts of women in the 6 months before and 6 months after the introduction of home administration of misoprostol. The main outcome measures were uptake of EMA, success of EMA and provision of long-acting reversible contraception (LARC) to women undergoing EMA.ResultsThere was a statistically significant increase in the uptake of EMA from 698/1075 (64.9%) women in the first study period to 823/1146 (71.8%) in the second study period. There was no statistically significant difference in the success rate of EMA: 99.3% and 98.9% in clinic and home misoprostol cohorts, respectively. There was also no statistically significant difference in the proportion of women provided with LARC: 37.7% and 33.7% in clinic and home misoprostol cohorts, respectively.ConclusionsSelf-administration of misoprostol at home increased uptake of EMA, with no effect on the high success rate that was previously seen with clinic administration of misoprostol. In addition, the reduced number of visits associated with home use of misoprostol has not affected the provision of effective contraception to women.

TERMINATION OF PREGNANCY LESS THAN 49 DAYS USING MIFEPRISTONE AND MISOPROSTOL

2011 ◽  
pp. 16-24
Author(s):  
Thi Kim Ngoc Do ◽  
Vu Quoc Huy Nguyen
Keyword(s):  
Abdominal Pain ◽  
Side Effects ◽  
Reproductive Health ◽  
Pregnant Women ◽  
Pregnancy Termination ◽  
Medical Abortion ◽  
Termination Of Pregnancy ◽  
Successful Pregnancy ◽  
Satisfaction Rate

Objectives: 1.To evaluate the effectiveness and safety of Mifepristone and Misoprostol in termination of pregnancy less than 49 days. 2. To evaluate the acceptability and side effects of that treatment scheme. Materials & Methods: 169 pregnant women less than <49 days demanding medical abortion at Can Tho Reproductive Health Center during the period of June 1st 2009 to May 30th 2010. Mifepristone 200mg was administered orally, followed by onsite monitoring during 30 minutes; Misoprostol 400 µg were administered orally 48 hours later by th facility at the center. Follow-up visit for 2 weeks was made after using Mifepristone. Results and Discussion: Rate of successful pregnancy termination was 95.3%. Mean duration between Mifepristone and Misoprostol use and abortion is 4.3 ± 3.7 hours. Satisfaction rate is 89.4%. Observed Mifepristone’s side effects include abdominal pain (35.8%), nausea (20.3%), and vomit (4.8%); Misoprostol’s side effects include abdominal pain (86.6%), nausea (33,7%), vomit (8,6%), fever/child, fatigue and diarrhea (7.5%). Conclusions: Mifepristone and Misoprostol are safe and highly effective for termination of pregnancy less than 49 days.

scholarly journals Acceptability of no-test medical abortion provided via telemedicine: analysis of patient-reported outcomes

2021 ◽  
pp. bmjsrh-2020-200954
Author(s):  
Chelsey Porter Erlank ◽  
Jonathan Lord ◽  
Kathryn Church
Keyword(s):  
Patient Reported Outcomes ◽  
Medical Abortion ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Post Procedure ◽  
High Satisfaction ◽  
First Choice ◽  
Patient Reported ◽  
At Home

IntroductionThe English government approved both stages of early medical abortion (EMA), using mifepristone and misoprostol under 10 weeks’ gestation, for at-home use on 30 March 2020. MSI Reproductive Choices UK (MSUK), one of the largest providers of abortion services in England, launched a no-test telemedicine EMA pathway on 6 April 2020. The objectives of this study were to report key patient-reported outcome measures and to assess whether our sample was representative of the whole population receiving no-test telemedicine EMA.MethodsA sample of all MSUK’s telemedicine EMA patients between April and August 2020 were invited to opt in to a follow-up call to answer clinical and satisfaction questions. A total of 1243 (13.7% of all telemedicine EMAs) were successfully followed-up, on average within 5 days post-procedure.ResultsPatients reported high confidence in telemedicine EMA and high satisfaction with the convenience, privacy and ease of managing their abortion at home. The sample responding were broadly equivalent to the whole population receiving telemedicine. No patient reported that they were unable to consult privately. The majority (1035, 83%) of patients reported preferring the telemedicine pathway, with 824 (66%) indicating that they would choose telemedicine again if COVID-19 were no longer an issue.ConclusionsTelemedicine EMA is a valued, private, convenient and more accessible option that is highly acceptable for patients seeking an abortion, especially those for whom in-clinic visits are logistically or emotionally challenging. Evidence that this pathway would be a first choice again in future for most patients supports the case to make telemedicine EMA permanent.

Sign in / Sign up

Export Citation Format

Share Document